In This Article:
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.
Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.
Is This 1 Momentum Stock a Screaming Buy Right Now?
Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
Novavax (NVAX)
Gaithersburg, MD-based Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company has also developed proprietary immune-stimulating saponin-based adjuvants, namely Matrix-M, added to the company’s vaccines to enhance immune response.
NVAX boasts a Momentum Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Novavax has seen some interesting price action recently; the stock is up 3.9% over the past one week and up 22.7% over the past four weeks. And in the last one-year period, NVAX has gained 49%. As for the stock's trading volume, 7,474,261 shares on average were traded over the last 20 days.
Momentum investors don't just pay attention to price changes; positive earnings play a crucial role, too. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $1 to $0.84 per share. NVAX boasts an average earnings surprise of 77.9%.
Investors should take the time to consider NVAX for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novavax, Inc. (NVAX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).